- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
TEVA / CEPHALON
M.6258
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Disclaimer :
The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.
SECTION 1.2
Description of the concentration
On 25 August 2011, the European Commission received a notification concerning the proposed acquisition of sole control within the meaning of Article 3(1)(b) of Regulation (EC) No. 139/2004 by Teva Pharmaceutical Industries Limited (“Teva”), an international pharmaceutical company headquartered in Israel, of Cephalon, Inc. (“Cephalon”), a U.S.-based international pharmaceutical company.
Teva is a global pharmaceutical company engaged in the development, production and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients around the world.
Cephalon is a global pharmaceutical company active in the development, production and marketing of generic and proprietary pharmaceutical products around the world. Cephalon is active in particular on central nervous system ("CNS") disorders, pain, oncology, inflammatory disease and regenerative medicine.